| Literature DB >> 27066324 |
Hiroaki Nozawa1, Soichiro Ishihara1, Koji Murono1, Koji Yasuda1, Kensuke Otani1, Takeshi Nishikawa1, Toshiaki Tanaka1, Tomomichi Kiyomatsu1, Keisuke Hata1, Kazushige Kawai1, Hironori Yamaguchi1, Toshiaki Watanabe1.
Abstract
Laparoscopy-assisted surgery has been widely accepted in the treatment of colorectal cancer. The aim of the present study was to investigate the feasibility and outcomes of laparoscopy-assisted combined resection for multiple colorectal cancers in comparison to open surgery. We retrospectively reviewed patients with synchronous multiple colorectal cancers who underwent combined resection resulting in two anastomotic sites by either open or laparoscopy-assisted surgery in the University of Tokyo Hospital between April 2005 and March 2015. Nine patients underwent laparoscopic surgery using five ports, whereas 16 underwent open surgery. Blood loss was less (median 65 vs 295 mL, p = 0.0015), but the operative time was longer (median 429 vs 310 min, p = 0.09) in the laparoscopic surgery group than in the open surgery group. No intergroup difference was observed in the number of lymph nodes retrieved (median 32 vs 27, p = 0.50). The frequency of clinically significant postoperative complications was also similar between the two groups. Our results suggest that laparoscopy-assisted combined resection is an acceptable alternative to open surgery for multiple colorectal cancers.Entities:
Keywords: Combined resections; Laparoscopic surgery; Multiple colorectal cancers; Two anastomoses
Year: 2016 PMID: 27066324 PMCID: PMC4781819 DOI: 10.1186/s40064-016-1948-4
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Fig. 1a Schematic positions of the camera port and trocars for laparoscopic resection of sigmoid, rectosigmoid, or rectal cancer b Schematic positions of the camera port and trocars for laparoscopic resection of cancer in another location
Clinical profile of patients
| LAP (n = 9) | OP (n = 16) | Total (n = 25) |
| |
|---|---|---|---|---|
| Gender | ||||
| Male | 7 (78 %) | 11 (69 %) | 18 (72 %) | 1.00 |
| Female | 2 (22 %) | 5 (31 %) | 7 (28 %) | |
| Age (years) | ||||
| Median (range) | 71 (61–81) | 71 (50–80) | 71 (50–81) | 0.54 |
| PS | ||||
| 0 | 8 (89 %) | 12 (75 %) | 20 (80 %) | 0.62 |
| 1 or more | 1 (11 %) | 4 (25 %) | 5 (20 %) | |
| BMI (kg/m2) | ||||
| Median (range) | 23 (19–26) | 22 (16–27) | 22 (16–27) | 0.33 |
| Comorbiditya | ||||
| None | 2 (22 %) | 6 (38 %) | 8 (32 %) | 0.66 |
| Cardiovascular | 5 (56 %) | 5 (31 %) | 10 (40 %) | 0.44 |
| Diabetes | 2 (22 %) | 3 (19 %) | 5 (20 %) | 1.00 |
| Pulmonary | 0 (0 %) | 2 (13 %) | 2 (8 %) | 0.52 |
| Hepatic | 0 (0 %) | 1 (6 %) | 1 (4 %) | 1.00 |
| Nephrological | 4 (44 %) | 1 (6 %) | 5 (20 %) | 0.04 |
| Neurological | 2 (22 %) | 2 (13 %) | 4 (16 %) | 0.60 |
| Hb (g/dL) | ||||
| Median (range) | 11.4 (9.7–14.3) | 11.3 (8.4–13.8) | 11.4 (8.4–14.3) | 0.52 |
| Alb (g/dL) | ||||
| Median (range) | 3.5 (3.1–4.3) | 3.7 (1.9–4.2) | 3.5 (1.9–4.3) | 0.56 |
| CEA (ng/mL) | ||||
| Elevated | 2 (22 %) | 10 (62 %) | 12 (48 %) | 0.10 |
| CA19-9 (U/mL) | ||||
| Elevated | 0 (0 %) | 5 (31 %) | 5 (20 %) | 0.12 |
Hb hemoglobin, Alb albumin, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9
aMultiple comorbidies in some cases
Findings of multiple CRCs
| LAP (n = 18) | OP (n = 38) | Total (n = 56) |
| |
|---|---|---|---|---|
| Obstruction | ||||
| Yes | 2 (22 %) | 6 (16 %) | 8 (14 %) | 1.00 |
| Location | ||||
| Cecum | 3 (16 %) | 5 (13 %) | 8 (14 %) | 0.86 |
| Ascending | 5 (28 %) | 9 (24 %) | 14 (25 %) | |
| Transverse | 2 (22 %) | 8 (21 %) | 10 (18 %) | |
| Descending | 0 (0 %) | 0 (0 %) | 0 (0 %) | |
| Sigmoid | 3 (16 %) | 11 (29 %) | 14 (25 %) | |
| Rectuma | 5 (28 %) | 5 (13 %) | 10 (18 %) | |
| Tumer size (mm)b | ||||
| Median (range) | 30 (0–88) | 33 (4–48) | 30 (0–88) | 0.20 |
| Histological type | ||||
| Diff. adenoca. | 18 (100 %) | 33 (87 %) | 51 (91 %) | 0.16 |
| Others | 0 (0 %) | 5 (13 %) | 5 (9 %) | |
| T | ||||
| Tis/T1 | 7 (39 %) | 13 (34 %) | 20 (36 %) | 0.16 |
| T2 | 6 (33 %) | 3 (8 %) | 9 (16 %) | |
| T3 | 5 (28 %) | 17 (45 %) | 22 (39 %) | |
| T4 | 0 (0 %) | 5 (13 %) | 5 (9 %) | |
| N | ||||
| N0 | 16 (88 %) | 30 (78 %) | 46 (82 %) | 0.96 |
| N1 | 1 (6 %) | 4 (11 %) | 5 (9 %) | |
| N2 | 1 (6 %) | 4 (11 %) | 5 (9 %) | |
| Stage | ||||
| 0 | 2 (11 %) | 4 (11 %) | 6 (11 %) | 0.44 |
| I | 10 (56 %) | 11 (29 %) | 21 (37 %) | |
| II | 4 (22 %) | 16 (42 %) | 20 (36 %) | |
| III | 2 (11 %) | 7 (18 %) | 9 (16 %) | |
Diff. adenoca. differentiated adenocarcinoma
aIncluding rectosigmoid
bIncluding lesions that showed a pathologically complete response to preoperative chemoradiation therapy
Details of surgery for each cancer
| LAP (n = 18) | OP (n = 32) | Total (n = 50) |
| |
|---|---|---|---|---|
| Surgical procedure | ||||
| Rt-sided colectomy | 9 (50 %) | 13 (41 %) | 22 (44 %) | 0.84 |
| Transverse colectomy | 0 (0 %) | 4 (12 %) | 4 (8 %) | |
| Lt-sided colectomy | 1 (5 %) | 2 (6 %) | 3 (6 %) | |
| Sigmoid colectomy | 3 (17 %) | 7 (22 %) | 10 (20 %) | |
| Anterior resection | 5 (28 %) | 6 (19 %) | 11 (22 %) | |
| Extent of lymphade-nectomy | ||||
| D1 | 1 (6 %) | 9 (28 %) | 10 (20 %) | 0.29 |
| D2 | 6 (33 %) | 6 (19 %) | 12 (24 %) | |
| D3 | 11 (61 %) | 17 (53 %) | 28 (56 %) | |
Rt-sided right-sided, Lt-sided left-sided
Overview of surgery for individual patients
| LAP (n = 9) | OP (n = 16) | Total (n = 25) |
| |
|---|---|---|---|---|
| Temporary stoma | ||||
| Yes | 1 (11 %) | 0 (0 %) | 1 (4 %) | 0.36 |
| Operative time (min) | ||||
| Median (range) | 429 (227–655) | 310 (171–461) | 330 (171–655) | 0.09 |
| Estimated blood loss (mL) | ||||
| Median (range) | 65 (30–210) | 295 (130–930) | 210 (30–930) | 0.0015 |
| Blood transfusion | ||||
| Yes | 0 (0 %) | 2 (13 %) | 2 (8 %) | 0.52 |
| Number of lymph nodes harvesteda | ||||
| Median (range) | 32 (15–60) | 27 (11–147) | 29 (11–147) | 0.50 |
| Complications | ||||
| None/grade 1 | 6 (67 %) | 12 (75 %) | 18 (72 %) | 0.67 |
| Grade 2 or more | 3 (33 %) | 4 (25 %) | 7 (28 %) | |
aCounting together for multiple cancers